Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

Astellas Pharma

アステラス製薬

4503 · TSE · Pharmaceutical · 3 articles

Financials Consolidated

Revenue¥2.14tn+11.9% year on yearConsolidated · FY3/26

Operating profit¥383bn+832.4% year on yearConsolidated · FY3/26

Net profit¥292bn+474.5% year on yearConsolidated · FY3/26

Dividend per share¥78.00FY3/26

Performance over time

Revenue
¥1.30tnFY3/22
¥1.52tnFY3/23
¥1.60tnFY3/24
¥1.91tnFY3/25
¥2.14tnFY3/26
Net profit (attributable)
¥124bnFY3/22
¥98.7bnFY3/23
¥17.0bnFY3/24
¥50.7bnFY3/25
¥292bnFY3/26
Op. cash flow
¥257bnFY3/22
¥328bnFY3/23
¥172bnFY3/24
¥195bnFY3/25
¥560bnFY3/26

People & pay

Employees, whole group14,099 peopleFY3/26

Employees, parent company (non-consolidated)4,081 peopleFY3/26

Average salary¥11.3mFY3/26

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOp. profitNet profit (attributable)EPSDividendTotal assetsTotal equityOp. cash flow
FY3/26¥2.14tn+11.9% year on year¥382.6bn¥291.5bn¥162.77¥78.00¥3.57tn¥1.83tn¥560bn
FY3/25¥1.91tn+19.2% year on year¥41.0bn¥50.7bn¥28.35¥74.00¥3.34tn¥1.51tn¥195bn
FY3/24¥1.60tn+5.6% year on year—¥17.0bn¥9.51¥70.00¥3.57tn¥1.60tn¥172bn
FY3/23¥1.52tn+17.2% year on year—¥98.7bn¥54.24¥60.00¥2.46tn—¥328bn
FY3/22¥1.30tn—¥124.1bn¥67.08¥50.00¥2.33tn—¥257bn

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100YBPK · IFRS, company-only figures: Japan GAAP. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:4503

Tokyo Brief coverage

  1. Astellas lifts profit guide as core margin heads for 30%

    Astellas lifted its full-year core operating profit forecast to ¥700bn from ¥620bn after first-half sales rose 23.4%, though currency added ¥41.2bn to core profit and the new guide assumes a weaker yen than April's.

  2. Astellas revenue passes ¥2.1tn as profit and ROE recover

    Revenue rose to ¥2,139,245,000,000 in the year to March 2026 from ¥1,912,323,000,000 a year earlier, while profit before tax jumped to ¥376,587,000,000 and net profit attributable to owners of parent to ¥291,535,000,000. ROE reached 17.4%, and a separate internal control report said financial-reporting controls were effective as of March 31.

All articles loaded · 3 shown

AGM votes

This season’s shareholder voting results.

1 meeting · data through

AGM votes
ProposalApprovalResultFiling
Election of 6 directors (excluding audit committee directors)
Original (Japanese)取締役(監査等委員である取締役を除く)6名選任の件
· 安川 健司
95.00%Votes cast: 95.02%ApprovedFiled  — filing S100YOHK
Election of 6 directors (excluding audit committee directors)
Original (Japanese)取締役(監査等委員である取締役を除く)6名選任の件
· 岡村 直樹
96.00%Votes cast: 96.00%ApprovedFiled  — filing S100YOHK
Election of 6 directors (excluding audit committee directors)
Original (Japanese)取締役(監査等委員である取締役を除く)6名選任の件
· 杉田 勝好
96.30%Votes cast: 96.37%ApprovedFiled  — filing S100YOHK
Election of 6 directors (excluding audit committee directors)
Original (Japanese)取締役(監査等委員である取締役を除く)6名選任の件
· 宮﨑 正啓
97.30%Votes cast: 97.36%ApprovedFiled  — filing S100YOHK
Election of 6 directors (excluding audit committee directors)
Original (Japanese)取締役(監査等委員である取締役を除く)6名選任の件
· 大野 洋一
97.30%Votes cast: 97.39%ApprovedFiled  — filing S100YOHK
Show 4 more meetings (9 total)
AGM votes
ProposalApprovalResultFiling
Election of 6 directors (excluding audit committee directors)
Original (Japanese)取締役(監査等委員である取締役を除く)6名選任の件
· マーク エネディ
97.30%Votes cast: 97.38%ApprovedFiled  — filing S100YOHK
Election of 3 audit committee directors
Original (Japanese)監査等委員である取締役3名選任の件
· 廣田 里香
93.20%Votes cast: 93.23%ApprovedFiled  — filing S100YOHK
Election of 3 audit committee directors
Original (Japanese)監査等委員である取締役3名選任の件
· 荒牧 知子
98.60%Votes cast: 98.68%ApprovedFiled  — filing S100YOHK
Election of 3 audit committee directors
Original (Japanese)監査等委員である取締役3名選任の件
· 高原 茂季
80.70%Votes cast: 80.75%ApprovedFiled  — filing S100YOHK

Approval is the ratio the company states (usually of the voting rights of shareholders present); votes cast are for ÷ (for + against + abstain).

† Percentage of votes cast; company did not state a ratio.

† Company-stated ratio differs from tallied votes.

Cross-holdings

Strategic shareholdings and sales, by fiscal year.

6 fiscal years · data through

Balance-sheet value
¥17.5bnFY3/22
¥12.7bnFY3/23
¥2.3bnFY3/24
¥0.7bnFY3/25
¥1.8bnFY3/26
Sale proceeds
¥0.4bnFY3/22
¥12.1bnFY3/23
—FY3/24
—FY3/25
—FY3/26

Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.

Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Mar 20262¥1.78bn0.10%——Filed  — filing S100YBPK
Show 5 more fiscal years (6 total)
Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Mar 20252¥682m0.05%——Filed  — filing S100VXR3
31 Mar 20242¥2.34bn0.15%——Filed  — filing S100TNPZ
31 Mar 20232¥12.7bn0.84%3¥12.1bnFiled  — filing S100SMI3
31 Mar 20225¥17.5bn1.20%2¥442mFiled  — filing S100O9T7
31 Mar 20215¥26.1bn1.88%1¥0Filed  — filing S100LIQN

Fund positioning

Current holdings disclosed by tracked funds.

25 funds · data through

Held by 25 tracked funds; largest weight 11.75%. Holdings as of 30 Oct 2026–20 Nov 2026.

Show 15 more funds (25 total)